KFDA Approves Distribution of BIOLASE Technology's (BLTI) Waterlase iPlus" All-Tissue Dental Laser Systems
Tweet
Share
E-mailGet Alerts BLTI Hot Sheet
Join SI Premium – FREE
BIOLASE Technology, Inc. (NASDAQ: BLTI) announced today that it has received approval from the Korean Food and Drug Administration (KFDA) to sell its Waterlase iPlus" all-tissue dental laser systems throughout South Korea.
South Korea has an estimated 25,000 dentists and 16,000 dental clinics, and their progressive dental practitioners have been particularly prone to adopting high-tech dental equipment, including more than 1,000 practices that currently use one or more BIOLASE dental lasers.
South Korea has an estimated 25,000 dentists and 16,000 dental clinics, and their progressive dental practitioners have been particularly prone to adopting high-tech dental equipment, including more than 1,000 practices that currently use one or more BIOLASE dental lasers.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Aligos Therapeutics Inc. (ALGS) Presents Positive Data from the ALG-097558 Phase 1 Study
- Medivir (MVIR) Granted FDA Rare Pediatric Disease Designation and Orphan Drug Designation for MIV-711
- Gain Therapeutics (GANX) Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287
Create E-mail Alert Related Categories
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
